0 results for 'Office of Device Evaluation of the FDA'
The return of the responsible corporate officer doctrine
The FDA increasingly uses it to attribute responsibility to corporate officers, even without evidence they were aware of the problematic conduct.Is FDA's New Chief Counsel a Change in Name Only?
The FDA's new chief counsel, Sheldon Bradshaw, has so far escaped the scrutiny faced by his predecessor, Daniel Troy, who was pilloried for his close ties to the drug industry. But Troy's controversial legal policies remain very much in force. Like Troy, Bradshaw offers one-on-one meetings with companies regulated by the agency, has kept low the number of warnings given about violations of regulations, and, perhaps most notably, continues to intervene on drug companies' behalf in private civil suits.View more book results for the query "Office of Device Evaluation of the FDA"
Nanomedicine Raises Intellectual Property Concerns
The term "nano" has come to signify quick, tiny and cutting-edge. Similarly, nanotechnology represents science at the cutting edge, as it converges with biology, medicine and information technology. One area of research expected to generate revolutionary contributions is cancer nanotechnology. The application of convergent technologies to cancer is creating more effective methods of detection, treatment and prevention, as well as raising a host of intellectual property issues.Learning from our neighbors about regulation of biosimilar drugs
The experience of foreign regulatory agencies may play an important role as the FDA develops its own standards.Good Legal Technology is Good Business: A Case for Bringing Employment Issues In-House
Brought to you by LexisNexis®
Download Now
Insights and Strategies for Effective Succession Planning in AM Law 100 Firms
Brought to you by Gallagher
Download Now
State AI Legislation Is on the Move in 2024
Brought to you by LexisNexis®
Download Now
2024 ESI Risk Management & Litigation Readiness Report
Brought to you by Pagefreezer
Download Now